Phosphodiesterase type 5 inhibitors and kidney disease

International Urology and Nephrology

Volumn 47, Issue 9, 2015, Pages 1521-1528

  Afsar, Baris ^a   Ortiz, Alberto ^b   Covic, Adrian ^c,d   Gaipov, Abduzhappar ^e   Esen, Tarik ^f   Goldsmith, David ^g   Kanbay, Mehmet ^f  

^a Konya Numune State Hospital   (Turkey)

^b 28400 Madrid   (Spain)

^c CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^d GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^e JSC National Scientific Medical Research Center   (Kazakhstan)

^f KOÇ UNIVERSITY   (Turkey)

^g GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Diabetic nephropathy; Hypertension; Kidney protection; Phosphodiesterase inhibitors

Indexed keywords

CILOSTAZOL; PENTOXIFYLLINE; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL; VARDENAFIL;

ALBUMINURIA; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DISEASE COURSE; END STAGE RENAL DISEASE; ERECTILE DYSFUNCTION; ESSENTIAL HYPERTENSION; HEART PROTECTION; HUMAN; INCIDENCE; INTERMITTENT CLAUDICATION; KIDNEY DISEASE; KIDNEY FUNCTION; METABOLIC ACIDOSIS; NEPHRECTOMY; PATHOGENESIS; PROTEIN INTAKE; PROTEIN RESTRICTION; PULMONARY HYPERTENSION; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; REPERFUSION INJURY; REVIEW; SINGLE DRUG DOSE; DRUG EFFECTS; METABOLISM; RENAL INSUFFICIENCY, CHRONIC;

DISEASE PROGRESSION; HUMANS; PHOSPHODIESTERASE 5 INHIBITORS; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 84940440236     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-015-1071-4     Document Type: Review

References (58)

1. Bello AK, Levin A, Manns BJ et al (2015) Effective CKD care in European countries: challenges and opportunities for health policy. Am J Kidney Dis 65:15–25
2. Mortality GBD (2015) Causes of death C: global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385:117–171
3. Klahr S, Schreiner G, Ichikawa I (1988) The progression of renal disease. N Engl J Med 318:1657–1666
4. Bae EH, Kim IJ, Joo SY et al (2012) Renoprotective effects of sildenafil in DOCA-salt hypertensive rats. Kidney Blood Press Res 36:248–257
5. Stefoni S, Cianciolo G, Baraldi O et al (2014) Emerging drugs for chronic kidney disease. Expert Opin Emerg Drugs 19:183–199
6. Drawz PE, Rosenberg ME (2011) Slowing progression of chronic kidney disease. Kidney Int Suppl 3(372–376):2013
7. Pippias M, Stel VS, Abad Diez JM et al (2015) Renal replacement therapy in Europe: a summary of the 2012 ERA-EDTA Registry Annual Report. Clin Kidney J 8:248–261
8. Gonzalez-Espinoza L, Ortiz A (2015) 2012 ERA-EDTA Registry Annual Report: cautious optimism on outcomes, concern about persistent inequalities and data black-outs. Clin Kidney J 8:243–247
9. Gordon J, Kopp JB (2011) Off the beaten renin-angiotensin-aldosterone system pathway: new perspectives on antiproteinuric therapy. Adv Chronic Kidney Dis 18:300–311
10. Fernandez-Fernandez B, Ortiz A, Gomez-Guerrero C et al (2014) Therapeutic approaches to diabetic nephropathy–beyond the RAS. Nat Rev Nephrol 10:325–346
11. Navarro-Gonzalez JF, Mora-Fernandez C, Muros de Fuentes M et al (2015) Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial. J Am Soc Nephrol 26:220–229
12. Kuno Y, Iyoda M, Shibata T et al (2011) Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in non-insulin-dependent Otsuka Long-Evans Tokushima Fatty rats. Br J Pharmacol 162:1389–1400
13. Chen HH, Huntley BK, Schirger JA et al (2006) Maximizing the renal cyclic 3′-5′-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure. J Am Soc Nephrol 17:2742–2747
14. Sohotnik R, Nativ O, Abbasi A et al (2013) Phosphodiesterase-5 inhibition attenuates early renal ischemia-reperfusion-induced acute kidney injury: assessment by quantitative measurement of urinary NGAL and KIM-1. Am J Physiol Renal Physiol 304:F1099–F1104
15. Jackson G, Benjamin N, Jackson N et al (1999) Effects of sildenafil citrate on human hemodynamics. Am J Cardiol 83:13C–20C
16. Mahmud A, Hennessy M, Feely J (2001) Effect of sildenafil on blood pressure and arterial wave reflection in treated hypertensive men. J Hum Hypertens 15:707–713
17. Kloner RA, Mitchell M, Emmick JT (2003) Cardiovascular effects of tadalafil in patients on common antihypertensive therapies. Am J Cardiol 92:47M–57M
18. Oliver JJ, Melville VP, Webb DJ (2006) Effect of regular phosphodiesterase type 5 inhibition in hypertension. Hypertension 48:622–627
19. Pomara G, Morelli G, Pomara S et al (2004) Cardiovascular parameter changes in patients with erectile dysfunction using pde-5 inhibitors: a study with sildenafil and vardenafil. J Androl 25:625–629
20. Wolk R, Smith WB, Neutel JM et al (2009) Blood pressure lowering effects of a new long-acting inhibitor of phosphodiesterase 5 in patients with mild to moderate hypertension. Hypertension 53:1091–1097
21. Webb DJ, Freestone S, Allen MJ et al (1999) Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Cardiol 83:21C–28C
22. Zusman RM, Prisant LM, Brown MJ (2000) Effect of sildenafil citrate on blood pressure and heart rate in men with erectile dysfunction taking concomitant antihypertensive medication. Sildenafil Study Group. J Hypertens 18:1865–1869
23. Pickering TG, Shepherd AM, Puddey I et al (2004) Sildenafil citrate for erectile dysfunction in men receiving multiple antihypertensive agents: a randomized controlled trial. Am J Hypertens 17:1135–1142
24. Ghiadoni L, Versari D, Taddei S (2008) Phosphodiesterase 5 inhibition in essential hypertension. Curr Hypertens Rep 10:52–57
25. Rodriguez-Iturbe B, Ferrebuz A, Vanegas V et al (2005) Early treatment with cGMP phosphodiesterase inhibitor ameliorates progression of renal damage. Kidney Int 68:2131–2142
26. Gardiner SM, March JE, Kemp PA et al (2005) Hemodynamic effects of phosphodiesterase 5 and angiotensin-converting enzyme inhibition alone or in combination in conscious SHR. J Pharmacol Exp Ther 312:265–271
27. Komers R, Anderson S (2003) Paradoxes of nitric oxide in the diabetic kidney. Am J Physiol Renal Physiol 284:F1121–F1137
28. Craven PA, Studer RK, DeRubertis FR (1994) Impaired nitric oxide-dependent cyclic guanosine monophosphate generation in glomeruli from diabetic rats. Evidence for protein kinase C-mediated suppression of the cholinergic response. J Clin Invest 93:311–320
29. Jeong KH, Lee TW, Ihm CG et al (2009) Effects of sildenafil on oxidative and inflammatory injuries of the kidney in streptozotocin-induced diabetic rats. Am J Nephrol 29:274–282
30. Fang L, Radovits T, Szabo G et al (2013) Selective phosphodiesterase-5 (PDE-5) inhibitor vardenafil ameliorates renal damage in type 1 diabetic rats by restoring cyclic 3′,5′ guanosine monophosphate (cGMP) level in podocytes. Nephrol Dial Transpl 28:1751–1761
31. Scheele WH, Gale JD, Clein V, Tamimi N, Le V, Walley RJ, Paez FG, El-Nahas M (2014) Selective inhibition of phosphodiesterase type 5 reduces macroalbuminuria in subjects with type 2 diabetes, and overt nephropathy. J Am Soc Nephrol Abstr (Suppl. 25)
32. Santi D, Giannetta E, Isidori AM et al (2015) THERAPY OF ENDOCRINE DISEASE: effects of chronic use of phosphodiesterase inhibitors on endothelial markers in type 2 diabetes mellitus: a meta-analysis. Eur J Endocrinol 172:R103–R114
33. Kalogeris T, Baines CP, Krenz M et al (2012) Cell biology of ischemia/reperfusion injury. Int Rev Cell Mol Biol 298:229–317
34. Cadirci E, Halici Z, Odabasoglu F et al (2011) Sildenafil treatment attenuates lung and kidney injury due to overproduction of oxidant activity in a rat model of sepsis: a biochemical and histopathological study. Clin Exp Immunol 166:374–384
35. Choi DE, Jeong JY, Lim BJ et al (2009) Pretreatment of sildenafil attenuates ischemia-reperfusion renal injury in rats. Am J Physiol Renal Physiol 297:F362–F370
36. Kucuk A, Yucel M, Erkasap N et al (2012) The effects of PDE5 inhibitory drugs on renal ischemia/reperfusion injury in rats. Mol Biol Rep 39:9775–9782
37. Guzeloglu M, Yalcinkaya F, Atmaca S et al (2011) The beneficial effects of tadalafil on renal ischemia-reperfusion injury in rats. Urol Int 86:197–203
38. Faddegon S, Best SL, Olweny EO et al (2012) Tadalafil for prevention of renal dysfunction secondary to renal ischemia. Can J Urol 19:6274–6279
39. Hosgood SA, Randle LV, Patel M et al (2014) Sildenafil citrate in a donation after circulatory death experimental model of renal ischemia-reperfusion injury. Transplantation 98:612–617
40. Guan Z, Miller SB, Greenwald JE (1995) Zaprinast accelerates recovery from established acute renal failure in the rat. Kidney Int 47:1569–1575
41. Solomon RJ, Mehran R, Natarajan MK et al (2009) Contrast-induced nephropathy and long-term adverse events: cause and effect? Clin J Am Soc Nephrol 4:1162–1169
42. Lauver DA, Carey EG, Bergin IL et al (2014) Sildenafil citrate for prophylaxis of nephropathy in an animal model of contrast-induced acute kidney injury. PLoS ONE 9:e113598
43. Selby NM, Shaw S, Woodier N et al (2009) Gentamicin-associated acute kidney injury. QJM 102:873–880
44. Morsy MA, Ibrahim SA, Amin EF et al (2014) Sildenafil ameliorates gentamicin-induced nephrotoxicity in rats: role of iNOS and eNOS. J Toxicol 2014:489382
45. Abdel-latif RG, Morsy MA, El-Moselhy MA et al (2013) Sildenafil protects against nitric oxide deficiency-related nephrotoxicity in cyclosporine A treated rats. Eur J Pharmacol 705:126–134
46. Essiz D, Sozmen M, Sudagidan M, et al (2015) Phosphodiesterase type 5 inhibition attenuates cyclosporine A induced nephrotoxicity in mice. Biotech Histochem 90(3):167–178
47. Hosogai N, Tomita M, Hamada K et al (2003) Phosphodiesterase type 5 inhibition ameliorates nephrotoxicity induced by cyclosporin A in spontaneous hypertensive rats. Eur J Pharmacol 477:171–178
48. Whitaker RM, Wills LP, Stallons LJ et al (2013) cGMP-selective phosphodiesterase inhibitors stimulate mitochondrial biogenesis and promote recovery from acute kidney injury. J Pharmacol Exp Ther 347:626–634
49. Lledo-Garcia E, Subira-Rios D, Ogaya-Pinies G et al (2011) Intravenous sildenafil as a preconditioning drug against hemodynamic consequences of warm ischemia-reperfusion on the kidney. J Urol 186:331–333
50. Serhatlioglu S, Kiris A, Kocakoc E et al (2003) Evaluation of the effects of sildenafil citrate (Viagra) on canine renal artery, carotid and aortic blood flow with the aid of color Doppler sonography. Urol Int 71:103–107
51. Ardicoglu A, Kocakoc E, Yuzgec V et al (2005) Hemodynamic effects of sildenafil citrate (Viagra) on segmental branches of bilateral renal arteries. Int Urol Nephrol 37:785–789
52. Degirmenci B, Acar M, Albayrak R et al (2006) Effects of sildenafil citrate (Viagra) on renal arteries: an evaluation with Doppler ultrasound. Urol Int 77:170–172
53. Dias AT, Rodrigues BP, Porto ML et al (2014) Sildenafil ameliorates oxidative stress and DNA damage in the stenotic kidneys in mice with renovascular hypertension. J Transl Med 12:35
54. Tapia E, Sanchez-Lozada LG, Soto V et al (2012) Sildenafil treatment prevents glomerular hypertension and hyperfiltration in rats with renal ablation. Kidney Blood Press Res 35:273–280
55. Lau DH, Mikhailidis DP, Thompson CS (2007) The effect of vardenafil (a PDE type 5 inhibitor) on renal function in the diabetic rabbit: a pilot study. In Vivo 21:851–854
56. Rosano GM, Aversa A, Vitale C et al (2005) Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 47:214–220; discussion 220–222
57. Yildiz H, Durmus AS, Simsek H et al (2011) Effects of sildenafil citrate on torsion/detorsion-induced changes in red blood cell and plasma lipid peroxidation, antioxidants, and blood hematology of male rats. Eur J Obstet Gynecol Reprod Biol 159:359–363
58. Hohenstein B, Daniel C, Wittmann S et al (2008) PDE-5 inhibition impedes TSP-1 expression, TGF-beta activation and matrix accumulation in experimental glomerulonephritis. Nephrol Dial Transpl 23:3427–3436